Home > Insider Trading > Filing (0000950170-23-051728)

Filing Details

Accession Number:: 0000950170-23-051728
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-10-03 19:13:42
Reporting Period:: 2023-09-29

Accepted Time:: 2023-10-03 19:13:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1880438	An2 Therapeutics Inc.	ANTX	()	E9

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1783165	Adjuvant Global Health Technology Fund, L.p.	C/O Adjuvant Capital, L.p. 501 Fifth Avenue, Suite 1404 New York NY 10017	No	No	No	No
1799812	Adjuvant Global Health Technology Fund De, L.p.	C/O Adjuvant Capital, L.p. 501 Fifth Avenue, Suite 1404 New York NY 10017	No	No	No	No
1935084	Adjuvant Capital Management, Llc	C/O Adjuvant Capital, L.p. 501 Fifth Avenue, Suite 1404 New York NY 10017	No	No	No	No
1935100	Adjuvant Capital Gp, L.p.	C/O Adjuvant Capital, L.p. 501 Fifth Avenue, Suite 1404 New York NY 10017	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-09-29	83,337	$16.28	2,086,343	No	4	S	Direct
Common Stock	Disposition	2023-09-29	15,764	$16.28	394,639	No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.
Common Stock	Disposition	2023-10-02	4,770	$16.07	2,081,573	No	4	S	Direct
Common Stock	Disposition	2023-10-02	902	$16.07	393,737	No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.
No	4	S	Direct
No	4	S	Indirect	By Adjuvant Global Health Technology Fund DE, L.P.

Footnotes

The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.95, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.